$TRVN News
Last published 10mo ago
- 10mo agoTRVNApproval of Olinvyk, Nda #210730 (Labeling)FDA Approved DrugsApproval Date: 12/22/2025; Drug Name: Olinvyk, Nda #210730; Active Ingredients: OLICERIDINE; Company: Trevena; Submission Status: Approval; Submission Classification: Labeling; Application Number: 210730
- 2y agoTRVNTrevena Reports Third Quarter 2024 Results and Provides Business UpdateGlobeNewswireCHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system
- 2y agoTRVNTrevena Announces Receipt of Nasdaq Delisting NotificationGlobeNewswireCHESTERBROOK, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system
- 2y agoTRVNTrevena Announces Reverse Stock SplitGlobeNewswireCHESTERBROOK, Pa., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system
- 2y agoTRVNTrevena Reports Second Quarter 2024 Results and Provides Business UpdateGlobeNewswireTRV045, novel S1P receptor modulator in development for the treatment of acute and chronic neuropathic pain and epilepsy, demonstrated sustained long-term analgesic effect and differentiated mechanism of action in
- 2y agoBRNSRCUSSGMTSNDX+2Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of DirectorsGlobeNewswireSAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to
- 2y agoTRVNTrevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty FinancingGlobeNewswireTrevena expects to receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINVYK US partnering and commercialization milestones Trevena further expects a $10 million
- 2y agoTRVNTrevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy ModelsGlobeNewswireTRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization TRV045 demonstrates statistically significant, dose-dependent
- 2y agoTRVNTrevena Reports First Quarter 2024 Results and Provides Business UpdateGlobeNewswireTRV045, novel S1P receptor modulator for chronic pain and epilepsy, continues to demonstrate a favorable tolerability profile Ongoing clinical PK study with optimized formulation of TRV045 advances, with data expected
- 2y agoTRVNTrevena Reports Fourth Quarter 2023 Results and Provides Corporate UpdateGlobeNewswireTRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies Company announces reduction of OLINVYK commercial support and review of
- 2y agoTRVNTrevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant ExerciseGlobeNewswireCHESTERBROOK, Pa., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. ("Trevena" or the "Company") (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for
- 2y agoTRVNTrevena Inc. Announces $4 Million Concurrent Private Placement and Warrant ExerciseGlobeNewswireCHESTERBROOK, Pa., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. ("Trevena" or the "Company") (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients
- 2y agoTRVNTrevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual MeetingGlobeNewswire-- Presentation highlighted promising results of TRV045 in nonclinical models of neuropathic pain including mechanical and cold-stimulus evoked nociceptive pain in a dose-related manner TRV045 selectively targets the
- 2y agoTRVNTrevena Awarded OLINVYK Agreement with Premier, Inc.GlobeNewswireCHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system
- 2y agoTRVNTrevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn InjuriesGlobeNewswireCHESTERBROOK, Pa., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system
- 2y agoTRVNTrevena, Inc. (TRVN) Q3 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoTRVNTrevena Reports Third Quarter 2023 Results and Provides Business UpdateGlobeNewswireCompany previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target engagement Company reported favorable safety and
- 3y agoTRVNTrevena to Release Third Quarter 2023 Financial Results on November 14, 2023GlobeNewswireCHESTERBROOK, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system
- 3y agoTRVNTrevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept StudiesGlobeNewswireTRV045 was well tolerated with results generally consistent with prior first-in-human study No drug-related adverse events and no serious adverse events reported No drug-related lymphopenia, bradycardia, or change in
- 3y agoTRVNTrevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists ConferenceGlobeNewswireContinuous respiratory monitoring data for ~200 complex surgical patients treated with IV OLINVYK at Cleveland Clinic and Wake Forest Baptist Health in the VOLITION study provides insights into respiratory compromise
- 3y agoTRVNTrevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business UpdateGlobeNewswire$15 million tranche from ex-US royalty-based financing, triggered by first commercial sale of OLINVYK by Jiangsu Nhwa, Trevena's partner in China New OLINVYK respiratory data from VOLITION ~200 patient
- 3y agoTRVNTrevena Announces Preliminary TRV045 Data from Two Proof-of-Concept Studies Evaluating S1PR Mechanism of Action and CNS Target EngagementGlobeNewswireTRV045 Demonstrated Statistically Significant Analgesic Effect in Capsaicin-induced Model of Neuropathic Pain in Target Engagement POC Study TMS POC Study Provided Statistically Significant Evidence of CNS Activity
- 3y agoTRVNTrevena Reports Second Quarter 2023 Results and Provides Business UpdateGlobeNewswireCompany announces database lock for TRV045 proof-of-concept TMS study evaluating potential for use in epilepsy; topline data expected 3Q 2023 TRV045 proof-of-concept study evaluating potential for use in acute and
- 3y agoTRVNTrevena, Inc. Appoints Mark Corrigan, M.D. to Board of DirectorsGlobeNewswireCHESTERBROOK, Pa. , July 20, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous
- 3y agoTRVNTrevena Announces New Topline OLINVYK Data Highlighting Reduced Cost per Admission from ARTEMIS Real-World Outcomes StudyGlobeNewswireOLINVYK-treated patients (n=201) had a statistically significant ~$8,750 (19%) lower cost per admission and ~1.4 day (20%) reduced average length of hospital stay, compared to matched patients treated with other IV
- 3y agoTRVNTrevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa PharmaceuticalGlobeNewswire$3 million milestone payment for Chinese approval of OLINVYK® (oliceridine) injection The Company also eligible to receive $15 million non-dilutive financing tranche from R-Bridge upon first commercial sale in
- 3y agoTRVNTrevena Regains Compliance with Nasdaq Listing and Reaffirms Expected Near-Term MilestonesGlobeNewswireCHESTERBROOK, Pa., May 30, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system
- 3y agoTRVNTrevena Reports First Quarter 2023 Results and Provides Business UpdateGlobeNewswireOLINVYK receives regulatory approval in China, triggering $3 million milestone payment from Company's China partner Jiangsu Nhwa Pharmaceutical Company expects to receive additional $15 million non-dilutive tranche from
- 3y agoACORIMRNLLYSILO+1Global Alzheimer's Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027PR NewswireFinancialNewsMedia.com News Commentary PALM BEACH, Fla., May 9, 2023 /PRNewswire/ -- Alzheimer's disease (AD) is a progressive and neurodegenerative disorder that attacks the brain's nerve cells or neurons, which
- 3y agoTRVNTrevena to Release First Quarter 2023 Financial Results on May 15, 2023GlobeNewswireCHESTERBROOK, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system
- 3y agoTRVNTrevena Announces Approval of OLINVYK in ChinaGlobeNewswireTrevena's partner, Jiangsu Nhwa, receives approval from Chinese National Medical Products Administration (NMPA) Approval achieves $3 million milestone to Trevena from Jiangsu Nhwa Additional $15 million to Trevena
- 3y agoTRVNTrevena to Participate in Three Upcoming ConferencesGlobeNewswireCHESTERBROOK, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system
- 3y agoTRVNTrevena Announces Initial Topline OLINVYK Data from ~200 Patient Real-World Clinical Outcomes StudyGlobeNewswireOLINVYK-treated patients had a statistically significant 1.6 day (~27%) reduction in average overall hospital length of stay compared to matched patients treated with other IV opioids, based on initial EMR analysis of
- 3y agoTRVNTrevena Reports Fourth Quarter 2022 Results and Provides Business UpdateGlobeNewswireCompany announces initial topline OLINVYK data including GI and cognitive outcomes, and length of stay data from ~200 patient real-world clinical outcomes study TRV045, a novel S1P receptor modulator, continues to
- 3y agoTRVNTrevena to Release Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023GlobeNewswireCHESTERBROOK, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous
- 3y agoTRVNTrevena Initiates Targeted Proof-of-Concept Study to Evaluate TRV045 as a Potential Treatment for Epilepsy and Other CNS DisordersGlobeNewswireCHESTERBROOK, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous
- 3y agoTRVNTrevena Announces Publication of OLINVYK Respiratory Physiology Study In ANESTHESIOLOGYGlobeNewswireOLINVYK demonstrated a reduced impact on respiratory depression compared to IV morphine, among elderly/overweight subjects Study consistent with prior results that suggest OLINVYK provides a reduced impact on
- 3y agoTRVNTrevena Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target EngagementGlobeNewswireNew Phase 1 clinical study designed to build on nonclinical evidence of anti-inflammatory signaling and potential disease-modifying effect of TRV045 in the treatment of epilepsy and other CNS disorders TRV045, a novel
- 3y agoTRVNTrevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data, and OLINVYK Clinical Neurocognitive and GI Data, at Recent Medical MeetingsGlobeNewswireTRV045 data reflected reduced seizure burden in nonclinical models of acute epilepsy presented at American College of Neuropsychopharmacology (ACNP) Annual Meeting OLINVYK poster presentation on reduced
- 3y agoTRVNTrevena Regains Compliance with Nasdaq Listing RequirementsGlobeNewswireCHESTERBROOK, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system
- 3y agoTRVNTrevena, Inc. Announces $8.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswireCHESTERBROOK, Pa., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel
- 4y agoTRVNTrevena Announces Reverse Stock SplitGlobeNewswireCHESTERBROOK, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system
- 4y agoTRVNTrevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor ModulatorGlobeNewswireTRV045 demonstrated a favorable tolerability profile with no reported SAEs and no lymphopenia Nonclinical study showed anti-inflammatory signaling, suggesting a potential disease-modifying effect of TRV045 in the
- 4y agoTRVNTrevena Reports Third Quarter 2022 Results and Provides Business UpdateGlobeNewswireOLINVYK commercialization progresses with Vizient contract and receipt of CMS outpatient pass-through reimbursement Positive Phase 1 topline results for TRV045, a novel S1P receptor modulator; no serious adverse events
- 4y agoTRVNTrevena to Release Third Quarter 2022 Financial Results on November 9, 2022GlobeNewswireCHESTERBROOK, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system
- 4y agoTRVNTrevena Announces OLINVYK Poster Presentation at the ANESTHESIOLOGY® 2022 Annual MeetingGlobeNewswireOLINVYK study demonstrated a statistically significant reduced impact on respiratory function compared to IV morphine, among elderly/overweight subjects OLINVYK oral presentation was selected as "Best of Abstracts:
- 4y agoTRVNTrevena to Participate at the H.C. Wainwright Annual Global Investment ConferenceGlobeNewswireCHESTERBROOK, Pa., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced
- 4y agoTRVNTrevena Reports Second Quarter 2022 Results and Provides Business UpdateGlobeNewswireOLINVYK post-approval strategy advances with positive topline cognitive function data and continued enrollment in VOLITION clinical outcomes study Phase 1 study for TRV045, a novel S1P receptor modulator, on track for year-end data readout; single asc
- 4y agoTRVNTrevena to Release Second Quarter 2022 Financial Results on August 11, 2022GlobeNewswireCHESTERBROOK, Pa., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced
- 4y agoTRVNTrevena, Inc. Announces Closing of Registered Direct Offering of Preferred StockGlobeNewswireCHESTERBROOK, Pa., July 29, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS